Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings.
iovance biotherapeutics股票周五交易上涨，该公司发布了2024年和2025年乐观的指导方针和超预期的第二季度收益。
On Thursday, the cancer cell therapy maker Iovance reported second-quarter sales of $31.12 million, surpassing the consensus of $24.6 million.
癌症细胞治疗制造商iovance周四公布了第二季度销售额为3112万美元，超过了2460万美元的共识。
The company reported EPS loss of $(0.34), down from $(0.47) a year ago, beating the consensus of $(0.35).
该公司报告的每股收益亏损$(0.34)，低于去年的$(0.47)，击败了$(0.35)的共识。
Also Read: Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy.
也可阅读：iovance biotherapeutics新获批皮肤癌细胞治疗药需要调整价格预测下调40％。
The second quarter of 2024 represents the first quarter of Amtagvi (lifileucel) sales in the U.S., with revenue of $12.8 million.
2024年第二季度代表了美国Amtagvi（lifileucel）销售的第一季度，收入为1280万美元。
The quarter's product revenue includes $18.3 million in sales for Proleukin, which is used in the Amtagvi treatment regimen and global commercial and clinical uses in other settings.
该季度的产品收入包括Proleukin的销售额达1830万美元，该产品用于Amtagvi治疗方案以及其他设置的全球商业和临床应用。
As of July 24, Iovance had cash, cash equivalents, investments, and restricted cash of $449.6 million, expected to be sufficient to fund current and planned operations into early 2026.
截至7月24日，iovance拥有44960万美元的现金、现金等价物、投资和受限现金，预计足以支持当前和计划的运营工作至2026年初。
At the 2024 ASCO Annual Meeting, Iovance announced updated clinical data for treating frontline advanced melanoma.
在2024年ASCO年会上，iovance公布了治疗一线晚期黑色素瘤的更新临床数据。
Guidance: Iovance expects significant quarter-over-quarter growth in product revenue to continue throughout 2024, 2025, and beyond as the adoption curve for Amtagvi steepens.
指导方针：iovance预计产品收入在2024年、2025年以及以后的季度将继续显著增长，因为Amtagvi的采用曲线加速。
The company says over 55 patients have been infused with Amtagvi since the first commercial infusion in April 2024.
该公司表示，自2024年4月首次进行商业输入以来，已有超过55名患者接受了Amtagvi的输入。
The company says with utilization broadening and the rate of infusions substantially increasing, total infusions during the third quarter have markedly exceeded infusions in the second quarter.
该公司表示，随着利用广泛和输入速度大幅增加，第三季度总输入量显著超过第二季度的输入量。
Revenues are expected to be $53 million to $55 million in the third quarter, versus the consensus of $49.05 million.
第三季度的收益预计为5300万美元至5500万美元，与4905万美元的共识相比有所增加。
For fiscal year 2024, the company expects sales of $160 million to $165 million versus a consensus of $143.21 million.
对于2024财年，该公司预计销售额为16000万美元至16500万美元，而共识为14321万美元。
Iovance Biotherapeutics expects that growth for Amtagvi will continue as existing authorized treatment centers (ATC) demand increases and new ATCs are onboarded.
iovance biotherapeutics预计，Amtagvi的增长将继续，因为现有授权治疗中心（ATC）的需求增加，新的ATC正在接入。
For fiscal 2025, product revenue is anticipated to be $450 million to $475 million, versus a consensus of $403.714 million. Gross margins are expected to increase to greater than 70% over the next several years.
对于2025财年，产品销售额预计为45000万美元至47500万美元，而共识为40371.4万美元。毛利率预计在未来几年将增加至70%以上。
Price Action: IOVA stock is up 25.19% at $9.94 at last check Friday.
股价表现：IOVA股票在上周五最后一次查看时上涨25.19％，达到9.94美元。
- What's Going On With Trump Media Stock On Friday?
- 特朗普媒体股票周五的情况如何？
Photo: Shutterstock
Photo: shutterstock